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ABSTRACT 
In two of three patients with peripheral vascular disease, systemic infu- 
sion of PGEl inhibited chemotactic factor induced secretion of glucos- 
aminidase from neutrophils. 
Abundant experimental evidence now supports a view that prosta- 
glandins of the E series can help regulate inflammatory responses. Al- 
though PGs appear to be local mediators of inflammation, (reviewed, 1) 
systemic administration of PGEl, 
methyl-PGE inflammation 
E2 and the stable El analog, 15-(S)-15- 
!! 
suppress in several experimental animal 
models (2, ,4,5). In vitro studies suggest that the ability of these 
compounds to limit inflammation may result from inhibition of 
polymorphonuclear leukocyte (PMN) functions such as aggregation (6), 
enzyme release (7), and directed migration (chemotaxis) (8). In this 
report we describe neutrophil function in 3 patients who received 
systemic treatment with PGEl for peripheral vascular disease. Two of the 
patients exhibited significant inhibition of leukocyte function following 
PGEl treatment. This represents one of the first observations in humans 
of altered neutrophil function after in vivo treatment with PGEl. 
Three patients with peripheral vascular disease were treated with 
intravenous (I.V.) administration of PGEl (kindly provided by Dr. William 
Martin, Upjohn Co., Kalamazoo, Michigan). Each patient had peripheral 
total white blood cell counts and white blood cell differential counts 
within normal ranges. The patients received PGEl by continuous I.V. 
infusion of 3pg/hr for 6 hours followed by a 6 hours "rest" period and a 
second 6 hour infusion period. Peripheral blood neutrophils were isolated 
by Ficol gradient separation from three patients before PGEl treatment and 
4 hours after the second 6 hour PGEl infusion period began. Secretion of 
the lysosomal enzyme N-acetyl-b-D-6glucosaminidase from cytochalasin B 
(Sng/ml) treated neutrophils (5x10 ) stimulated with N-formyl-methionyl- 
leucyl-phenylalanine (F-met-leu-phe) was determined (9). A range of 
F-met-leu-phe concentration was examined. This was compared to a similar 
dose response as determined in a healthy control individual. The 
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response of the control individual's neutrophils to F-met-leu-phe was 
similar to the response of two other healthy individual's neutrophils. 
e release (MER) was determined as follows: per 
The effects of systemic infusion of PGEl on chemotactic factor induced 
secretion of glucosaminidase from neutrophils is shown in Fig. 1A. Before 
PGE infusion, enzyme secretion from PMNs from patients #l and #2 was not 
sidificantly different from control values. However, during treatment a 
decrease of 15.3% (p c.01) and 33.4% (p c.01) in MER from pre-treatment 
values was seen in _gatients #l and #2, respectively. MER was achieved with 
approximately 5x10 M F-met-leu-phe. Patient #3 showed a significant 
decrease in MER compared to the control individual even before treatment 
with PGEl. Although the value of MER of patient #3 increased slightly 
during treatment it is not known why this patients initial studies were 
significantly less than the control individual. Thus, it is difficult to 
interpret this patient's response to PGEl treatment. 
After stimulation at various doses of F-met-leu-phe, Figures 1 (B) 
and 1 (C) show the variation in enzyme release of the neutrophils from 
patients #l and #2. Significant inhibition of enzyme release 
(glucosaminidase activity) was seen throughout the F-met-leu-phe dose 
response range (Figs. 1B E 1C). 
Addition of PGEl to PMNs in vitro inhibits neutrophil chemotaxis (8 
aggregation (6), and endocytosis induced lysosomal enzyme release (7). 
In addition, systemic administration of PGEl, or its analog 15-(S)-15- 
methyl-PGEl prolongs survival and retards progression of 
glomerulonephritis in NZB/NZW F hybrid mice (3), inhibits the joint 
inflammation of chronic adjuvan + arthritis in rats (4), suppresses the 
dermal Arthus reaction (5), and inhibits vascular permeability changes 
due to vasoactive mediators (6). However, there is a paucity of data in 
humans regarding the effects of systemic administration of PGEl. 
1, 
Recent studies have demonstrated physiologic effects of prostacyclin 
in vivo. Following intravenous administration of prostacyclin in humans 
with peripheral vascular disease, Szczelik et al (10) reported 
improvement in peripheral vascular perfusion. Although we have examined 
only a small number of patients, our data with humans parallel 
observations in experimental animals; that is, in vivo treatment with 
PGEl induces significant functional defects in GuGhils. Thus, PGE; 
treatment in this manner has the potential to produce significant 
anti-inflammatory effects in vivo. It is important to underscore that 
induction of chemotactic dzezin PGE treated rats was of an order far 
greater than could be achieved by in vi ro exposure of neutrophils to -1 
PGEl (5). Thus, administered PGE mayinfluence the function of cells 
involved in the inflammatory response in ways that can be used to 
clinical advantage. 
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FIGURE 1: 
'(a) Percent maximum enzyme release (MER) in three patients compared 
to a control individual. m = prior to PGE treatment. 
0 ?? during PGEl treatment. fi = p < . 01. Students 
T-test was used to compare the patient's MER to the control 
individual's MER. 
(b) and (cl 
Comparison of the effect of the concentration of F-met-leu-phe 
in the presence of cytochalasin B (5 ug/ml) on the secretion of 
glucosaminidase (expressed as the change in absorbance at 410 
nm) from neutrophils isolated from patient #l (b) and patient 
#2 (c) during PGE treatment.+ 
(0) = control $ndividual, - SEM 
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